MPP-Home

en / fr

THE MEDICINES PATENT POOL AND GILEAD SCIENCES SIGN LICENCE FOR BICTEGRAVIR

The MPP announced on 4 October 2017 a licence with Gilead Sciences for bictegravir (BIC), now under review in the United States and the European Union as part of a once-daily, single-tablet HIV regimen.

The Medicines Patent Pool Welcomes Extension of MPP-Gilead HIV Licences to Include Belarus, Malaysia and Ukraine

The MPP welcomes biopharmaceutical company Gilead Sciences' announcement that it will extend its HIV licences signed with the MPP to include three additional countries, namely Belarus, Malaysia and Ukraine.

BRISTOL-MYERS SQUIBB, MEDICINES PATENT POOL EXTEND LICENCE FOR ATAZANAVIR TO 122 DEVELOPING COUNTRIES

The MPP has signed an extension of its licensing agreement with biopharmaceutical company Bristol-Myers Squibb (BMS) to further increase access to atazanavir (ATV), part of the World Health Organization-preferred second-line treatment for adults and children.

Message from the Executive Director on the MPP strategy

The MPP has a clear mission: to increase access and innovation in the fields of HIV, hepatitis C and tuberculosis treatment for people living in developing countries.

Who We Are

The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to HIV, hepatitis C and tuberculosis treatments in low- and middle-income countries.

Vision & Mission

Our Model

Strategy

Governance & Team

Funding

Who We Work With

MedsPaL

The Medicines Patents & Licences Database

MedsPaL provides information on the patent and licensing status of selected HIV, hepatitis C and tuberculosis medicines in low- and middle-income countries.

Additional information and disclaimer

Transparency in the MPP

All MPP licences are publicly available in their entirety on the MPP website. This is unprecedented in the pharmaceutical field.

Licence Overview

Update on Progress of MPP Sublicensees

Forecasting

MPP in Numbers

Hover over the numbers to find out more

9 patent holders with MPP signed agreements

12.9

12.9 million patient-years through MPP’s generic partners

20 generic manufacturers and product developers sublicensed from the MPP

17 products licensed to the MPP

120+

120+ ongoing pharmaceutical development projects

87% to 91%

87% to 91% of people living with HIV in developing countries covered by the MPP adult licences

92 to 131

92 to 131 countries covered by MPP adults licences

312

312 million dollars saved, from 2012 to December 2016

Latest News

11 October 2017

The Medicines Patent Pool and Otsuka Sign Memorandum of Understanding for Paediatric Formulations of Delamanid for Multidrug-Resistant Tuberculosis

Geneva, 11 October 2017 — The Medicines Patent Pool (MPP) announced that it has signed a Memorandum of Understanding (MoU) with Otsuka to accelerate the development and manufacturing of, and access to, paediatric formulations containing delamanid for multidrug-resistant tuberculosis (MDR-TB). Delamanid 50mg tablet was recently added to the World Health Organization’s Essential Medicines List for Children signalling its priority for health programmes globally. Otsuka is currently developing a suitable paediatric formulation of the treatment for younger children. The MoU outlines broad areas of collaboration between the parties, including seeking funding to have a third-party manufacturer develop appropriate paediatric formulations, and engaging in necessary licensing activities to move this forward. Importantly, it also envisions the parties seeking out future areas of cooperation in the field of MDR-TB treatment to address broader unmet patient needs. The MPP, originally focused on HIV treatment acce...

04 October 2017

The Medicines Patent Pool and Gilead Sciences Sign Licence for Bictegravir

As part of a novel, once-daily, single-tablet HIV treatment, bictegravir could offer new option for people living with HIV in low- and middle-income countries Geneva, 4 October 2017 — The Medicines Patent Pool (MPP) today announced a licence with Gilead Sciences for bictegravir (BIC), now under review in the United States and the European Union as part of a once-daily, single-tablet HIV regimen. The licence allows manufacturers to develop and sell generic medicines containing BIC, if approved in the United States, in 116 low- and middle-income countries where more than 30 million people live with HIV. “Bictegravir-containing combinations could offer improved, simplified treatment options, crucial for people living in resource-limited settings,” said Greg Perry, Executive Director of the Medicines Patent Pool. “With this new licence, we look forward to our long-running collaboration with Gilead Sciences continuing to deliver significant results.” Bictegravir is an integrase inhibitor in the same class...

25 July 2017

Bristol-Myers Squibb, Medicines Patent Pool Extend Licence for Atazanavir to 122 Developing Countries

Extension of 2013 agreement allows an additional 1.4 million people living with HIV to benefit from sublicensed generics of World Health Organization-recommended antiretroviral Paris, 25 July 2017 — The Medicines Patent Pool (MPP) has signed an extension of its licensing agreement with biopharmaceutical company Bristol-Myers Squibb (BMS) to further increase access to atazanavir (ATV), part of the World Health Organization-preferred second-line treatment for adults and children. Announced during an MPP-jointly hosted satellite at the 9th International AIDS Society Conference on HIV Science in Paris this evening, the amendment adds 12 countries to the 110 included in the original 2013 agreement. Home to 1.4 million people living with HIV (PLHIV), the additional countries are: Algeria, Cook Islands, Egypt, Equatorial Guinea, Indonesia, Malaysia, Morocco, Niue, the Philippines, Tunisia, Ukraine and Vietnam. The agreement now covers 89% of PLHIV in low- and middle-income countries. “Our ATV licence has al...

Videos

Endorsements

“Successful cooperation of the Ministry of Health of Belarus with the Medicines Patent Pool is crucial in light of our current work to achieve the “90-90-90” goals and put an end to the epidemic in the country which is only possible when access to affordabl...”

Tweets by MedsPatentPool

View on Twitter